BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, Scudiero O, Limongelli G, Pirro M, Calabrò P. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors 2020;46:367-80. [PMID: 31999032 DOI: 10.1002/biof.1619] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Cesaro A, Acerbo V, Raucci G, Calabrò P. Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? European Heart Journal Supplements 2022;24:I34-I37. [DOI: 10.1093/eurheartjsupp/suac099] [Reference Citation Analysis]
2 Ou Z, Yu Z, Liang B, Zhao L, Li J, Pang X, Liu Q, Xu C, Dong S, Sun X, Li T. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients. Front Cardiovasc Med 2022;9:939791. [PMID: 36017088 DOI: 10.3389/fcvm.2022.939791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pressly J, Fornoni A. The Many Lives of PCSK9: Therapeutic Implications. Kidney360 2022;3:1296-1298. [DOI: 10.34067/kid.0003272022] [Reference Citation Analysis]
4 Nava-Salazar S, Flores-Pliego A, Pérez-Martínez G, Parra-Hernández S, Vanoye-Carlo A, Ibarguengoitia-Ochoa F, Perichart-Perera O, Reyes-Muñoz E, Solis-Paredes JM, Espino Y Sosa S, Estrada-Gutierrez G. Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9. Reprod Sci 2022. [PMID: 35467263 DOI: 10.1007/s43032-022-00943-w] [Reference Citation Analysis]
5 Zhang Q, Liu Z, Wang Q, Li X. Low cholesterol is not associated with depression: data from the 2005-2018 National Health and Nutrition Examination Survey. Lipids Health Dis 2022;21. [DOI: 10.1186/s12944-022-01645-7] [Reference Citation Analysis]
6 Grewal T, Buechler C. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. IJMS 2022;23:1070. [DOI: 10.3390/ijms23031070] [Reference Citation Analysis]
7 Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX, Li JJ. NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids Health Dis 2022;21:3. [PMID: 34996457 DOI: 10.1186/s12944-021-01610-w] [Reference Citation Analysis]
8 Marques P, Domingo E, Rubio A, Martinez-Hervás S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Biomed Pharmacother 2022;145:112460. [PMID: 34864314 DOI: 10.1016/j.biopha.2021.112460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
9 Limongelli G, Monda E, Lioncino M, Bossone E. Rare Cardiovascular Diseases: From Genetics to Personalized Medicine. Heart Fail Clin 2022;18:xix-xi. [PMID: 34776088 DOI: 10.1016/j.hfc.2021.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cesaro A, Fimiani F, Gragnano F, Moscarella E, Schiavo A, Vergara A, Akioyamen L, D'Erasmo L, Averna M, Arca M, Calabrò P. New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. Heart Fail Clin 2022;18:177-88. [PMID: 34776078 DOI: 10.1016/j.hfc.2021.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
11 Bensenor I, Padilha K, Lima IR, Santos RD, Lambert G, Ramin-Mangata S, Bittencourt MS, Goulart AC, Santos IS, Mill JG, Krieger JE, Lotufo PA, Pereira AC. Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study. Front Genet 2021;12:728526. [PMID: 34659352 DOI: 10.3389/fgene.2021.728526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Petersen-Uribe Á, Kremser M, Rohlfing AK, Castor T, Kolb K, Dicenta V, Emschermann F, Li B, Borst O, Rath D, Müller KAL, Gawaz MP. Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease. Int J Mol Sci 2021;22:11179. [PMID: 34681838 DOI: 10.3390/ijms222011179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
13 Ito M, Hiwasa T, Oshima Y, Yajima S, Suzuki T, Nanami T, Sumazaki M, Shiratori F, Funahashi K, Li SY, Iwadate Y, Yamagata H, Jambaljav B, Takemoto M, Yokote K, Takizawa H, Shimada H. Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer. Front Oncol 2021;11:708039. [PMID: 34504788 DOI: 10.3389/fonc.2021.708039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Huang H, Yu X, Li L, Shi G, Li F, Xiao J, Yun Z, Cai G. Atherogenic index of plasma is related to coronary atherosclerotic disease in elderly individuals: a cross-sectional study. Lipids Health Dis 2021;20:68. [PMID: 34247637 DOI: 10.1186/s12944-021-01496-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
15 Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A, Moscarella E, Gragnano F, Salvatore T, Rinaldi L, Calabrò P, Sasso FC. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int J Mol Sci 2021;22:5863. [PMID: 34070765 DOI: 10.3390/ijms22115863] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
16 Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer: Rethinking the link. Biomed Pharmacother 2021;140:111758. [PMID: 34058443 DOI: 10.1016/j.biopha.2021.111758] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
17 Liu F, Wang Z, Cao X, Pan Y, Zhang E, Zhou J, Zheng L. Relationship between small dense low-density lipoprotein cholesterol with carotid plaque in Chinese individuals with abnormal carotid artery intima-media thickness. BMC Cardiovasc Disord 2021;21:216. [PMID: 33906606 DOI: 10.1186/s12872-021-02023-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
19 Diggelmann F, Bengs S, Haider A, Epprecht G, Beeler AL, Etter D, Wijnen WJ, Portmann A, Warnock GI, Treyer V, Grämer M, Todorov A, Mikail N, Rossi A, Fuchs TA, Pazhenkottil AP, Buechel RR, Tanner FC, Kaufmann PA, Gebhard C, Fiechter M. Potential Impact of Statins on Neuronal Stress Responses in Patients at Risk for Cardiovascular Disease. J Pers Med 2021;11:261. [PMID: 33916056 DOI: 10.3390/jpm11040261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Mäkelä KA, Jokelainen J, Stenbäck V, Auvinen J, Järvelin MR, Tulppo M, Leppäluoto J, Keinänen-Kiukaanniemi S, Herzig KH. PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy. J Clin Med 2021;10:994. [PMID: 33801208 DOI: 10.3390/jcm10050994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Al-Mrabeh A. β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies. Biomedicines 2021;9:226. [PMID: 33672162 DOI: 10.3390/biomedicines9020226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Feder S, Wiest R, Weiss TS, Aslanidis C, Schacherer D, Krautbauer S, Liebisch G, Buechler C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis. Lipids Health Dis 2021;20:6. [PMID: 33461570 DOI: 10.1186/s12944-021-01431-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
23 Chaulin AM, Duplyakov DV. Biomarkers of acute myocardial infarction: diagnostic and prognostic value. Part 2 (Literature review). Journal of Clinical Practice 2020;11:70-82. [DOI: 10.17816/clinpract48893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
24 Guerrero-Beltrán CE, Mijares-Rojas IA, Salgado-Garza G, Garay-Gutiérrez NF, Carrión-Chavarría B. Peptidic vaccines: The new cure for heart diseases? Pharmacol Res 2021;164:105372. [PMID: 33316382 DOI: 10.1016/j.phrs.2020.105372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Bensenor I, Padilha K, Lima IR, Santos RD, Lambert G, Ramin-mangata S, Bittencourt MS, Goulart AC, Santos IS, Mill JG, Krieger JE, Lotufo PA, Pereira AC. Genome-wide association of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) plasma levels in the ELSA-Brasil study.. [DOI: 10.1101/2020.12.03.409631] [Reference Citation Analysis]
26 Macchi C, Favero C, Ceresa A, Vigna L, Conti DM, Pesatori AC, Racagni G, Corsini A, Ferri N, Sirtori CR, Buoli M, Bollati V, Ruscica M. Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance. Cardiovasc Diabetol 2020;19:187. [PMID: 33143700 DOI: 10.1186/s12933-020-01158-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
27 Huang YQ, Liu XC, Lo K, Feng YQ, Zhang B. A dose-independent association of triglyceride levels with all-cause mortality among adults population. Lipids Health Dis 2020;19:225. [PMID: 33059659 DOI: 10.1186/s12944-020-01400-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX, Li JJ. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol 2020;19:167. [PMID: 33023603 DOI: 10.1186/s12933-020-01142-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
29 Bonaterra GA, Bender K, Wilhelm B, Schwarzbach H, Metz S, Kelber O, Weiser D, Metz J, Kinscherf R. Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits. BMC Cardiovasc Disord 2020;20:420. [PMID: 32942987 DOI: 10.1186/s12872-020-01703-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hernández JL, Baldeón C, López-Sundh AE, Ocejo-Vinyals JG, Blanco R, González-López MA. Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study. Lipids Health Dis 2020;19:200. [PMID: 32861241 DOI: 10.1186/s12944-020-01377-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Cesaro A, Schiavo A, Moscarella E, Coletta S, Conte M, Gragnano F, Fimiani F, Monda E, Caiazza M, Limongelli G, D'Erasmo L, Riccio C, Arca M, Calabrò P. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. J Cardiovasc Med (Hagerstown) 2021;22:151-61. [PMID: 32858625 DOI: 10.2459/JCM.0000000000001077] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
32 Masson W, Lobo M, Siniawski D, Molinero G, Masson G, Huerín M, Nogueira JP. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. Lipids Health Dis 2020;19:111. [PMID: 32460779 DOI: 10.1186/s12944-020-01297-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]